Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Operating Expenses | 28,154 | 38,702 | 38,737 | 45,512 | 38,297 |
| Operating Income | -28,154 | -38,702 | -38,737 | -45,512 | -38,297 |
| Other Income | 1,832 | 758 | -682 | 5,577 | -1,448 |
| Pre-tax Income | -26,322 | -37,944 | -39,419 | -39,935 | -39,746 |
| Net Income Continuous | -26,322 | -37,944 | -39,419 | -39,935 | -39,746 |
| Net Income | $-26,322 | $-37,944 | $-39,419 | $-39,935 | $-39,746 |
| EPS Basic Total Ops | -0.87 | -1.26 | -1.31 | -1.33 | -1.40 |
| EPS Basic Continuous Ops | -0.87 | -1.26 | -1.31 | -1.33 | -1.40 |
| EPS Diluted Total Ops | -0.87 | -1.26 | -1.31 | -1.33 | -1.40 |
| EPS Diluted Continuous Ops | -0.87 | -1.26 | -1.31 | -1.33 | -1.40 |
| EBITDA(a) | $-28,154 | $-38,702 | $-38,737 | $-45,512 | $-38,297 |